The Goldman Sachs Group Raises Gossamer Bio (NASDAQ:GOSS) Price Target to $8.00

Gossamer Bio (NASDAQ:GOSS) had its target price upped by The Goldman Sachs Group from $7.00 to $8.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock.

A number of other equities analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th. Wedbush restated an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a research note on Friday.

Gossamer Bio Price Performance

Shares of NASDAQ:GOSS opened at $1.04 on Friday. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.55. The business has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $0.99. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The firm has a market cap of $236.31 million, a price-to-earnings ratio of -3.25 and a beta of 1.82.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The business had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $3.95 million. On average, analysts expect that Gossamer Bio will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On Gossamer Bio

A number of large investors have recently made changes to their positions in GOSS. Octagon Capital Advisors LP grew its stake in shares of Gossamer Bio by 99.7% during the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after purchasing an additional 9,162,117 shares during the period. Alyeska Investment Group L.P. grew its stake in shares of Gossamer Bio by 52.7% during the 4th quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock valued at $7,968,000 after purchasing an additional 3,041,058 shares during the period. Monaco Asset Management SAM grew its stake in shares of Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after acquiring an additional 1,520,721 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Gossamer Bio by 720.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after acquiring an additional 825,047 shares during the period. Finally, Allostery Investments LP bought a new position in shares of Gossamer Bio during the 4th quarter valued at approximately $555,000. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.